RecruitingPhase 1NCT05025488

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

A Phase I Open Label Peptide Based Vaccine in Patients With Myeloproliferative Neoplasm Harboring CALR Mutations

Sponsor

Marina Kremyanskaya

Enrollment

10 participants

Start Date

Apr 4, 2023

Study Type

INTERVENTIONAL

Conditions

Myelofibrosis Essential Thrombocythemia MPN

Summary

The primary objective of this study is to assess the safety and tolerability of administrating mutated-CALR peptide Vaccine to patients with MPN. The researchers plan to enroll 10 patients over a 12 month period. Maximum length of participation in 80 weeks. Patients will be asked to complete questionnaires, bone marrow biopsies, research lab collection, and standard of care lab draw. This research will be taking place only at The Mount Sinai Hospital, specifically at the Ruttenberg Treatment Center.

Eligibility

Min Age: 18 Years

Inclusion Criteria16

Subjects must be ≥18 years of age at the time of signing the informed consent form.
Confirmed diagnosis of chronic phase MPN:
Previously treated or relapsed/refectory high risk ET
Low to intermediate 1 risk (DIPSS 0-1) PMF or ET-MF
Verified mutation in CALR exon 9
PS ≤ 2
Adequate organ function:
Absolute neutrophil count ≥ 1000/mm3,
Platelet count ≥ 50,000/mm3,
Creatinine ≤ 2.5 mg/dL,
Total bilirubin ≤ 2 mg/dL, (except in patients with Gilbert Syndrome who can have total bilirubin < 3.0 mg/dL)
Transaminases < 3 times above the upper limits of the institutional normal.
Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to starting study medication and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks prior to first dose of vaccine. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy.
Ability to understand and the willingness to sign a written informed consent.
Ability to adhere to the study visit schedule and all protocol requirements.
Subjects receiving cytoreductive therapy with hydroxyurea must be on a stable dose for at least 8 weeks prior to week 1.

Exclusion Criteria12

Other invasive malignancy in the past 3 years except non-melanoma skin cancer, localized cured prostate cancer and early stage breast cancer on HRT.
Active autoimmune disease.
Uncontrolled serious infection.
Known immunodeficiency.
Pregnant and breastfeeding women.
Not willing to use contraception.
Current use of immunosuppressive medications including steroids.
Current JAK inhibitor use.
Current use of IFN (use of anagrelide is permitted).
Treatment with other experimental drugs within 30 days of week 1.
Treatment with any MPN directed therapy unless otherwise noted within 5 half-lives of week 1.
Any significant psychiatric/medical condition per investigators judgment.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPeptide-based vaccine

ten (10) doses of Mutant-CALR peptides with KLH as helper peptide (in the first vaccine only). Mutant-CALR vaccine will administered every 2 weeks for the first 4 doses and then every 4 weeks for additional 6 doses. Maintenance Treatment The protocol allows for a continued administration of up to four (4) additional Mutant-CALR vaccine and four (4) Poly-ICLC administrations, 12 weeks apart.

DRUGPoly ICLC

ten (10) doses of Poly-ICLC. Poly-ICLC will be given on weeks 1, 3, 5, 7, 11, 15, 19, 23, 27 and 31. each Poly-ICLC dose must be given the day after the corresponding Mut-CALR vaccination.